Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study of GC1118 in Recurrent Glioblastoma Patients With High Epidermal Growth Factor Receptor (EGFR) Amplification

NCT03618667 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT03618667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03618667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study of GC1118 in Recurrent Glioblastoma Patients With High Epidermal Growth Factor Receptor (EGFR) Amplification
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Completed
Start date
January 22, 2018
Completion date
April 28, 2022
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr amplification, glioblastoma, adult